Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
09:51:21 EDT Sat 04 May 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
News for U:CRVS from 2023-05-04 to 2024-05-03 - 23 items
News Releases
In The News
Other
CA
US
Date
Sym
Price
Type
Headline
2024-05-02 16:02
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
2024-05-02 08:30
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
2024-04-09 16:01
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
2024-03-19 16:02
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-03-13 16:02
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024
2024-02-12 08:30
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases
2024-02-08 16:05
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma
2024-02-06 16:05
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer
2024-01-23 17:00
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
2023-12-09 12:00
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
2023-11-07 16:01
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 ‚ Financial Results
2023-11-02 09:15
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
2023-11-01 19:32
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
2023-10-31 16:02
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
2023-09-06 16:05
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA
2023-08-08 16:01
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-08-01 08:30
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023
2023-07-06 12:59
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)
2023-06-29 07:00
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR ‚ Precision Cancer Medicine International Conference
2023-06-15 07:00
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma
2023-05-31 08:30
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference
2023-05-17 09:00
U
U:CRVS
News Release
200
Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma
2023-05-08 16:01
U
U:CRVS
News Release
200
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results